一般演題（口演）36 免疫チェックポイント阻害剤（Nivo+Ipi）

[O36-1] 1st-line（1L）nivolumab+ipilimumab+chemo（N+I+C）in metastatic（m）NSCLC：CheckMate 9LA 5y data

^○Satoshi Ikeda¹, Martin Reck², Tudor-Eliade Ciuleanu³, Michael Schenker⁴, Stephanie Bordenave⁵, Manuel Cobo-Dols⁶, Oscar Juan-Vidal⁷, Niels Reinmuth⁸, Enriqueta Felip⁹, Juliana Menezes¹⁰, Ying Cheng¹¹, Hideaki Mizutani¹², David P. Carbone¹³, Shun Lu¹⁴, Thomas John¹⁵, Takekazu Aoyama¹⁶, Nan Hu¹⁶, Laura Eccles¹⁶, Luis G. Paz-Ares¹⁷ (1.Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan, 2.Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany, 3.Institutul Oncologic Prof Dr Ion Chiricuţă and University of Medicine and Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania, 4.SF Nectarie Oncology Center, Craiova, Romania, 5.L'institut du Thorax, Nantes, France, 6.Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain, 7.Hospital Universitario La Fe, Valencia, Spain, 8.Asklepios Lung Clinic, Munich-Gauting, Germany, 9.Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology（VHIO）, Barcelona, Spain, 10.Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil, 11.Jilin Cancer Hospital, Changchun, Jilin, China, 12.Saitama Cancer Center, Saitama, Japan, 13.The Ohio State University Comprehensive Cancer Center and the Pelotonia Institute for Immuno-Oncology, Columbus, OH, USA, 14.Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, 15.Austin Hospital, Heidelberg, VIC, Australia, 16.Bristol Myers Squibb, Princeton, NJ, USA, 17.Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain)